Aclarion's Nociscan Technology Uncovers Immune-Biomarker Link in Back Pain Study
Event summary
- Aclarion's Nociscan MRS technology identified elevated propionic acid levels in lumbar discs linked to immune activation in MC1 patients.
- Study received the 2026 ISSLS Best Paper Award, conducted by University of Zurich, UCSF, and REACH Center.
- Findings suggest Nociscan could expand beyond surgical planning to differentiate immune-related back pain subtypes.
- Propionic acid levels correlated with systemic immune activation, particularly involving B-cells.
The big picture
Aclarion's findings challenge the traditional view of chronic back pain as purely mechanical, suggesting a broader role for immune biomarkers. This could position Nociscan as a key player in the shift toward personalized spine care, potentially expanding its addressable market beyond surgical decision support. The study's recognition with the ISSLS Best Paper Award lends credibility to these early-stage findings, though commercialization remains a multi-year horizon.
What we're watching
- Clinical Expansion
- Whether Aclarion can validate Nociscan's expanded utility in immune-related back pain cases.
- Regulatory Pathways
- The pace at which Aclarion pursues additional indications for Nociscan beyond surgical planning.
- Competitive Positioning
- How this discovery affects Aclarion's standing in the precision spine care market.